Core Viewpoint - Green Leaf Pharmaceutical (02186) has successfully included five new products in the National Medical Insurance Drug List (2025) and the Commercial Health Insurance Innovative Drug List (2025) [1] Group 1: New Product Inclusion - The five new products include: - Mimesin® (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai® (Paliperidone Palmitate Injection (II)) are newly included in the National Medical Insurance Drug List [1] - Zanbija® (Injectable Lurbinectedin) has been successfully included in the Commercial Health Insurance Innovative Drug List [1] - Baituowei® (Injectable Goserelin Microspheres) and Ruiketuo® (Injectable Risperidone Microspheres (II)) have successfully renewed their inclusion in the National Medical Insurance Drug List [1]
绿叶制药(02186)五款新产品成功纳入2025年国家医保药品目录或商保创新药目录